Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
[HTML][HTML] Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
AA Butt, P Yan, OS Shaikh - Plos one, 2024 - journals.plos.org
Background In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
[HTML][HTML] Molnupiravir, nirmatrelvir/ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and time until …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
[HTML][HTML] The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data
Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …
Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada
Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …
[HTML][HTML] Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
[HTML][HTML] Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
R Flisiak, D Zarębska-Michaluk, M Rogalska… - Pharmacological …, 2022 - Springer
Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
[HTML][HTML] Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Y Suzuki, Y Shibata, H Minemura, T Nikaido… - Clinical and …, 2023 - Springer
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
[HTML][HTML] Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …